<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02821819</url>
  </required_header>
  <id_info>
    <org_study_id>IB012016</org_study_id>
    <nct_id>NCT02821819</nct_id>
  </id_info>
  <brief_title>Random-start Ovarian Stimulation in Egg-donors (ROSE)</brief_title>
  <acronym>ROSE</acronym>
  <official_title>Random-start Ovarian Stimulation in Egg-donors (ROSE) Trial: a Self-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Bernabeu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Bernabeu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this prospective single-center study is to evaluate the laboratory outcome
      after random start ovarian stimulation in oocyte donors. The study will be performed in
      egg-donors but this type of treatment has the potential to be implemented in general
      infertility population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study group will start ovarian stimulation randomly in different moments throughout the
      menstrual cycle.

      Randomization will take place on day 2-3 of the menstrual cycle, according to a list of
      random allocation of treatments and egg-donors will be assigned to random start ovarian
      stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle
      and during luteal phase starting at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11.

      Egg-donors will receive urinary follicle stimulating hormone (FSH) 150-225 IU/d in
      gonadotropin-releasing hormone (GnRH) antagonist protocol with cetrorelix acetate 0,25 mg/d
      starting five days after ovarian stimulation and a GnRH agonist trigger with triptorelin 0,2
      mg to induce the final follicular maturation. Transvaginal ultrasound and serum analysis
      (estradiol, progesterone, LH and FSH) will be included for cycle monitoring.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Difficult recruitment
  </why_stopped>
  <start_date type="Actual">January 10, 2017</start_date>
  <completion_date type="Actual">January 12, 2018</completion_date>
  <primary_completion_date type="Actual">January 12, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Mature Eggs</measure>
    <time_frame>Up to 24 hours from the oocyte collection</time_frame>
    <description>When collected, eggs retain numerous cells (granulosa or cumulus cells) surrounding the oocyte; this structure is termed as the cumulus oocyte complex (COC). Few hours later (2-4 hs), the oocyte is denuded from these cumulus cells, allowing for a clearer observation of the maturity status (presence or absence of a metaphase II) of the oocyte. The percentage of mature eggs represents the proportion resulting from dividing the total number of COCs collected by the number of metaphase II oocytes and multiplied by 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fertilization Rate</measure>
    <time_frame>24 hours after day of oocyte collection</time_frame>
    <description>Percentage of properly fertilized eggs after microinjection (ICSI) method</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Random start ovarian stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. They will receive urinary follicle stimulating hormone (FSH) 150-225 International units / daily (IU/d) and five days later the gonadotropin-releasing hormone (GnRH) antagonist: cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.
Interventions:
Random start ovarian stimulation
Gonadotrophins: Urinary FSH 150-225 IU/d
GnRH antagonists: Cetrorelix 0,25 mg/d
GnRH agonist for triggering: Triptorelin 0,2 mg single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Random start ovarian stimulation</intervention_name>
    <description>Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.</description>
    <arm_group_label>Random start ovarian stimulation</arm_group_label>
    <other_name>Ovarian stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotrophins</intervention_name>
    <description>Urinary FSH 150-225 IU/d</description>
    <arm_group_label>Random start ovarian stimulation</arm_group_label>
    <other_name>Ovarian stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH antagonist</intervention_name>
    <description>Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation</description>
    <arm_group_label>Random start ovarian stimulation</arm_group_label>
    <other_name>Ovarian stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH agonist</intervention_name>
    <description>GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.</description>
    <arm_group_label>Random start ovarian stimulation</arm_group_label>
    <other_name>Final follicular maturation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Premenopausal women

          -  18-35 years old

          -  FSH levels &lt; 10 IU/liter

          -  Antral follicle count (AFC) &gt; 10

          -  Regular cycles

          -  Body Mass Index (BMI) &lt; 28

          -  Signed informed consent

        Exclusion Criteria:

          -  Polycystic ovary syndrome (PCOS) patients

          -  Allergy to gonadotrophins

          -  Concomitant participation in other trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan C Castillo, Md. PhD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Bernabeu</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Instituto Bernabeu</name>
      <address>
        <city>Alicante</city>
        <zip>03016</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.institutobernabeu.com</url>
    <description>Setting</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/27114329</url>
    <description>Reference</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 19, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 4, 2016</study_first_posted>
  <results_first_submitted>September 16, 2018</results_first_submitted>
  <results_first_submitted_qc>July 11, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2019</results_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Bernabeu</investigator_affiliation>
    <investigator_full_name>Juan Carlos Castillo</investigator_full_name>
    <investigator_title>Md. PHd.</investigator_title>
  </responsible_party>
  <keyword>ovarian stimulation</keyword>
  <keyword>random</keyword>
  <keyword>egg donation</keyword>
  <keyword>antagonist</keyword>
  <keyword>gnrh agonist trigger</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/19/NCT02821819/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Random Start Ovarian Stimulation</title>
          <description>Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at luteinizing hormone (LH) peak +3,+5,+7,+9 or +11. They will receive urinary follicle stimulating hormone (FSH) 150-225 International units / daily (IU/d) and five days later the gonadotropin-releasing hormone (GnRH) antagonist will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.
Interventions:
Random start ovarian stimulation
Gonadotrophins: Urinary FSH 150-225 IU/d
GnRH antagonists: Cetrorelix 0,25 mg/d
GnRH agonist for triggering: Triptorelin 0,2 mg single dose
Gonadotrophins: Urinary FSH 150-225 IU/d
GnRH antagonist: Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
GnRH agonist: GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Random Start Ovarian Stimulation</title>
          <description>Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at LH peak +3,+5,+7,+9 or +11. They will receive urinary FSH 150-225 IU/d and five days later cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.
Interventions:
Random start ovarian stimulation
Gonadotrophins: Urinary FSH 150-225 IU/d
GnRH antagonists: Cetrorelix 0,25 mg/d
GnRH agonist for triggering: Triptorelin 0,2 mg single dose
Gonadotrophins: Urinary FSH 150-225 IU/d
GnRH antagonist: Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
GnRH agonist: GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.2" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Mature Eggs</title>
        <description>When collected, eggs retain numerous cells (granulosa or cumulus cells) surrounding the oocyte; this structure is termed as the cumulus oocyte complex (COC). Few hours later (2-4 hs), the oocyte is denuded from these cumulus cells, allowing for a clearer observation of the maturity status (presence or absence of a metaphase II) of the oocyte. The percentage of mature eggs represents the proportion resulting from dividing the total number of COCs collected by the number of metaphase II oocytes and multiplied by 100.</description>
        <time_frame>Up to 24 hours from the oocyte collection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Random Start Ovarian Stimulation</title>
            <description>Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at LH peak +3,+5,+7,+9 or +11. They will receive urinary FSH 150-225 IU/d and five days later cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.
Interventions:
Random start ovarian stimulation
Gonadotrophins: Urinary FSH 150-225 IU/d
GnRH antagonists: Cetrorelix 0,25 mg/d
GnRH agonist for triggering: Triptorelin 0,2 mg single dose
Gonadotrophins: Urinary FSH 150-225 IU/d
GnRH antagonist: Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
GnRH agonist: GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Mature Eggs</title>
          <description>When collected, eggs retain numerous cells (granulosa or cumulus cells) surrounding the oocyte; this structure is termed as the cumulus oocyte complex (COC). Few hours later (2-4 hs), the oocyte is denuded from these cumulus cells, allowing for a clearer observation of the maturity status (presence or absence of a metaphase II) of the oocyte. The percentage of mature eggs represents the proportion resulting from dividing the total number of COCs collected by the number of metaphase II oocytes and multiplied by 100.</description>
          <units>Percentage of mature eggs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The sample size was calculated assuming a non-inferiority margin of 5 eggs and a standard deviation (SD) of 6.7. A unilateral alpha level of 0.05 was stablished. With the aim to show that the difference in the mean number of collected eggs will not exceed 5, a statistical power of 80% required 30 patients per group (1:1 allocation, total sample: 60).</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The sample size was calculated assuming a non-inferiority margin of 5 eggs SD 6.7. A unilateral alpha level of 0.05 was stablished. With the aim to show that the difference in the mean number of collected eggs will not exceed 5, a statistical power of 80% required 30 patients per group (1:1 allocation, total sample: 60).</non_inferiority_desc>
            <p_value>0.8</p_value>
            <p_value_desc>a priori threshold for statistical significance: &lt;0.05</p_value_desc>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>8.1</dispersion_value>
            <ci_n_sides>1-Sided</ci_n_sides>
            <other_analysis_desc>Since the number of collected eggs constitutes the main outcome of the study, the sample size was calculated assuming a non-inferiority margin of 5 eggs with an standard deviation of 6.7. A unilateral alpha level of 0.05 was stablished. With the aim to show that the difference in the mean number of collected eggs will not exceed 5, a statistical power of 80% required 30 patients per group (1:1 allocation, total sample: 60).
Statistical analysis was performed using t-student test for continuous variables and chi-square test for categorical parameters. A P value of &lt;.05 was considered significant.</other_analysis_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>The sample size was calculated assuming a non-inferiority margin of 5 eggs SD 6.7. A unilateral alpha level of 0.05 was stablished. With the aim to show that the difference in the mean number of collected eggs will not exceed 5, a statistical power of 80% required 30 patients per group (1:1 allocation, total sample: 60). Statistical analysis used t-student test for continuous variables and chi-square test for categorical parameters.</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The sample size was calculated assuming a non-inferiority margin of 5 eggs SD 6.7. A unilateral alpha level of 0.05 was stablished. With the aim to show that the difference in the mean number of collected eggs will not exceed 5, a statistical power of 80% required 30 patients per group (1:1 allocation, total sample: 60). Statistical analysis used t-student test for continuous variables and chi-square test for categorical parameters.</non_inferiority_desc>
            <p_value>0.8</p_value>
            <p_value_desc>a priori threshold for statistical significance: &lt;0.05</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>82</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fertilization Rate</title>
        <description>Percentage of properly fertilized eggs after microinjection (ICSI) method</description>
        <time_frame>24 hours after day of oocyte collection</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Random Start Ovarian Stimulation</title>
            <description>Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at LH peak +3,+5,+7,+9 or +11. They will receive urinary FSH 150-225 IU/d and five days later cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.
Interventions:
Random start ovarian stimulation
Gonadotrophins: Urinary FSH 150-225 IU/d
GnRH antagonists: Cetrorelix 0,25 mg/d
GnRH agonist for triggering: Triptorelin 0,2 mg single dose
Gonadotrophins: Urinary FSH 150-225 IU/d
GnRH antagonist: Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
GnRH agonist: GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.</description>
          </group>
        </group_list>
        <measure>
          <title>Fertilization Rate</title>
          <description>Percentage of properly fertilized eggs after microinjection (ICSI) method</description>
          <units>Percentage of properly fertilized eggs</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Statistical analysis was performed using t-student test for continuous variables and chi-square test for categorical parameters. A P value of &lt;.05 was considered significant.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>71.1</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Random Start Ovarian Stimulation</title>
          <description>Egg-donors will be assigned to random start ovarian stimulation: During follicular phase starting at day 5,7,9,11 or 13 of the menstrual cycle and during luteal phase at LH peak +3,+5,+7,+9 or +11. They will receive urinary FSH 150-225 IU/d and five days later cetrorelix acetate 0,25 mg/d will be added until achieving criteria for receiving triptorelin 0,2 mg to induce final follicular maturation. Egg collection will take place 36 hours later.
Interventions:
Random start ovarian stimulation
Gonadotrophins: Urinary FSH 150-225 IU/d
GnRH antagonists: Cetrorelix 0,25 mg/d
GnRH agonist for triggering: Triptorelin 0,2 mg single dose
Gonadotrophins: Urinary FSH 150-225 IU/d
GnRH antagonist: Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
GnRH agonist: GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination. Only random-start follicular phase stimulation was completed.
01 patient was withdrawn from analysis due to protocol violation: error in administration of medication</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Juan Carlos Castillo</name_or_title>
      <organization>Instituto Bernabeu</organization>
      <phone>+34650562634</phone>
      <email>jcastillo@institutobernabeu.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

